Neither remdesivir nor HCQ affect viral clearance in hospitalized patients with COVID-19
(American College of Physicians) NOR-Solidarity, an independent, add-on, randomized controlled trial to the World Health Organization (WHO) Solidarity trial, found that neither remdesivir nor hydroxychloroquine (HCQ) affected viral clearance in hospitalized patients with COVID-19. The WHO Solidarity trial showed no effect of remdesivir or hydroxychloroquine (HCQ) on mortality but did not assess antiviral effects of these drugs. The findings are published in Annals of Internal Medicine.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
More News: COVID-19 | Hydroxychloroquine | Infectious Diseases | Internal Medicine | International Medicine & Public Health | WHO